港股異動 | 力高集團(1622.HK)大漲近10% 1月實現合約銷售約為26億
格隆匯2月2日丨力高集團(1622.HK)低位彈升,大幅拉昇至9.69%,報2.83港元,總市值100.5億港元。力高集團公吿,截至2021年1月31日止1個月,公司實現合約銷售約為26億元人民幣,建築面積約30.6萬平方米。此外,1月4號,力高集團宣佈"集團銷售額突破400億元",在新冠疫情肆虐的2020年,力高集團的主要業績指標跑贏了多數同行。聯合國際曾予力高集團“BB-”國際長期發行人評級,展望“穩定”。預計力高將繼續以謹慎的方式進行規模擴張和地域多元化,同時保持其健康的利潤率並控制其財務槓桿的增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.